×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANVS – annovis bio, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
08:00 am
anvs
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
Medium
Report
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
11/11
08:09 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/11
08:00 am
anvs
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
High
Report
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
11/7
08:00 am
anvs
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
Low
Report
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
10/31
08:00 am
anvs
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
Low
Report
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
10/25
08:11 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock.
Medium
Report
Annovis Bio, Inc. (NYSE: ANVS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock.
10/22
08:11 am
anvs
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 [Financial Post (Toronto, Ontario, Canada)]
10/22
08:00 am
anvs
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Low
Report
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:19 am
anvs
Form 8-K Annovis Bio, Inc. For: Nov 12
Medium
Report
Form 8-K Annovis Bio, Inc. For: Nov 12
11/8
05:09 pm
anvs
Form 10-Q Annovis Bio, Inc. For: Sep 30
Medium
Report
Form 10-Q Annovis Bio, Inc. For: Sep 30
10/15
08:13 am
anvs
Form 8-K Annovis Bio, Inc. For: Oct 15
Medium
Report
Form 8-K Annovis Bio, Inc. For: Oct 15
9/30
08:39 am
anvs
Form 8-K Annovis Bio, Inc. For: Sep 30
Medium
Report
Form 8-K Annovis Bio, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/28
Annovis Bio Announces Pricing of Initial Public Offering
44.6%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
TOP News Decliners
1/30
Form 424B4 Annovis Bio, Inc.
-26.7%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: